Clear Street Group Inc. Invests $56.38 Million in Novo Nordisk A/S $NVO

Clear Street Group Inc. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 1,016,000 shares of the company’s stock, valued at approximately $56,378,000. Novo Nordisk A/S comprises approximately 0.2% of Clear Street Group Inc.’s investment portfolio, making the stock its 28th biggest position.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Capital International Investors boosted its position in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 1.5% during the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after purchasing an additional 187,789 shares in the last quarter. Folketrygdfondet raised its stake in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after purchasing an additional 117,370 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its holdings in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after buying an additional 649,390 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, HSBC reaffirmed a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $49.93.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Stock Down 0.1%

NVO opened at $37.99 on Friday. The stock’s fifty day simple moving average is $50.14 and its 200 day simple moving average is $51.77. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $82.57. The stock has a market cap of $169.61 billion, a PE ratio of 10.95 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is presently 52.74%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.